News FAMHP

There are 928 result(s) found based on your search criteria

21-30 from 928 result(s)

Call for Belgian laboratories to apply as EU reference laboratories in the field of in vitro diagnostic medical devices

The European Commission has issued a second call for Member State laboratories to submit applications to become a European Union reference laboratory for in vitro diagnostic medical devices. The designation of these laboratories is provided for in Article 100 of Regulation (EU) 2017/746 on in vitro diagnostic medical devices.

Unregulated advanced therapy medicinal products pose serious risks to health

The FAMHP, EMA and the Heads of European Medicines Agencies warn about unregulated products in the EU, including dendritic cell cancer therapies.

The 2023 annual biovigilance report is now available

Biovigilance ensures systematic monitoring, from donor selection to recipient follow-up, in order to guarantee safer and more efficient use of tissues and cells. In this 2023 report, all SAEs and SARs that occurred during the processing and use of SoHO from 1 January 2023 to 30 June 2024 have been compiled.

Critical Medicines Alliance issues recommendations for addressing medicines shortages at European level

In April 2024, the Critical Medicines Alliance was established under the Belgian Presidency of the Council of the European Union. The goal of the Alliance is to foster collaboration among policymakers and stakeholders, and develop a robust and responsive system for the supply of critical medicines in the European Union. Today, on 28 February 2025, the Critical Medicines Alliance presents its strategic report. This report will be used as the basis for new European legislation on medicines shortages: the Critical Medicines Act.

Give your opinion on genetically modified hepatitis B vaccine

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified hepatitis B vaccine vaccine LAV-YF17D/HBc (AVX70371). The public consultation will take place from 28 February 2025 to 30 March 2025.

Marketing authorisation for two vaccines against bluetongue virus serotype 3

In January 2025, the Committee for Veterinary Medicinal Products of the European Medicines Agency issued a positive opinion on an application for authorisation under Article 25 for the immunological veterinary medicinal products Syvazul BTV-3 and Bluevac-3. Both products will therefore shortly be given a marketing authorisation.

Simultaneous National Scientific Advice: continuation and further development in 2025

Since February 2020, the European Union Innovation Network has been running a pilot project for simultaneous national scientific advice provided by multiple national competent authorities at the same time. Following a positive evaluation of the results of the simultaneous national scientific advice pilot project at the Heads of Medicines Agencies meeting in January 2025, the continuation of the concept was supported.

Deadline for the registration of sales volumes of veterinary medicinal products

Marketing authorisation holders must submit the 2024 sales volumes of veterinary medicinal products to the UPD by 28 February 2025.

PRAC January 2025: EMA started a review of medicines containing semaglutide following concerns regarding an increased risk of non-arteritic anterior ischemic optic neuropathy

During its January 2025 meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) started a review of medicines containing semaglutide following concerns regarding an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).

Operation Shield V: Belgian authorities seize 349 386 pills and tablets in action against counterfeit medicines, doping and food supplements

Customs, the Federal Police, the Federal Agency for Medicines and Health Products (FAMHP), the Federal Agency for the Safety of the Food Chain (FASFC) and anti-doping organisations (NADO Flanders, ONAD Fédération Wallonie-Bruxelles, ONADO Brussels) took part in operation SHIELD V, coordinated by Europol. This operation ran from April to November 2024 and targeted counterfeit medicines, doping and food supplements.

21-30 from 928 result(s)